title: Nephrotoxicity of contrast media in high-risk patients with renal insufficiency: comparison of low- and high-osmolar contrast agents.
abstract: We have compared the renal effects of ioxitalamate, ioxaglate, and iopamidol in patients with chronic renal failure. Sixty consecutive patients with an estimated creatinine clearance (ECRCl) less than 60 ml/min were randomly assigned to receive either ioxitalamate, iopamidol, or ioxaglate. All patients received 500 cm3 isotonic saline before the procedure. Serum creatinine and ECRCl were estimated before, 1 and 2 or 3 days after the procedure. There was no statistical difference between the three groups with respect to age, sex, weight, renal function, amount of iodine, and type of procedure. Mean serum creatinine and ECRCl remained unchanged after administration of contrast media. No patient had nephrotoxicity or acute oliguria requiring dialysis as a result of the administration of contrast material. The number of patients with an increase in the serum creatinine level greater than 10% from the basal value did not differ in the treatment groups. The maximal increases in serum creatinine were 52 mumol/l (29%) in the ioxitalamate group, 56 mumol/l (18%) in the ioxaglate group, and 57 mumol/l (23%) in the iopamidol group (p = NS). Using a population carefully randomized and matched for renal insufficiency, we could not show any differences in nephrotoxicity between these three contrast agents. Clinically serious renal impairment was uncommon in our study, regardless of the contrast agent used. However, the interpretation of these favorable findings requires a cautionary note. All patients in this study were well hydrated before and after uro-/angiography, and none had a recent renal injury or a treatment with a nephrotoxic agent that would predispose to injury from contrast material.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département de Néphrologie, Hôpital Pitié-Salpêtrière, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Deray
authors.forename: M F
authors.initials: MF
authors.lastname: Bellin
authors.forename: H
authors.initials: H
authors.lastname: Boulechfar
authors.forename: B
authors.initials: B
authors.lastname: Baumelou
authors.forename: F
authors.initials: F
authors.lastname: Koskas
authors.forename: A
authors.initials: A
authors.lastname: Baumelou
authors.forename: J
authors.initials: J
authors.lastname: Grellet
authors.forename: C
authors.initials: C
authors.lastname: Jacobs
mesh_terms: D000368:Aged; D003287:Contrast Media / Q000633:toxicity*; D005260:Female; D006801:Humans; D007479:Iopamidol / Q000633:toxicity; D007483:Iothalamic Acid / Q000031:analogs & derivatives / Q000633:toxicity; D007485:Ioxaglic Acid / Q000633:toxicity; D007668:Kidney / Q000187:drug effects*; D007676:Kidney Failure, Chronic / Q000000981:diagnostic imaging* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D011859:Radiography; D012307:Risk Factors
chemical_list: D003287:Contrast Media; D007483:Iothalamic Acid; C002587:ioxitalamic acid; D007479:Iopamidol; D007485:Ioxaglic Acid